Soligenix Targets Bundibugyo Virus with Thermostable Vaccine Following 100% Primate Protection
SNGX•Soligenix announced that CEPI opened a call for Bundibugyo virus vaccine proposals due June 12, 2026, leveraging its thermostable multivalent subunit platform. Preclinical tests demonstrated 100% protection in non-human primates and ambient-temperature stability, positioning the company to expedite vaccine development for outbreak response.
1. CEPI Call for Bundibugyo Vaccine Proposals
On June 8, CEPI issued a call for proposals for protein-based thermostable subunit vaccines targeting Bundibugyo virus, with applications due by June 12, 2026. Soligenix plans to submit its proposal in collaboration with Dr. Axel Lehrer of the University of Hawaiʻi, building on platform compatibility demonstrated in prior research.
2. Preclinical Results and Vaccine Platform
Soligenix’s bivalent and trivalent constructs, formulated with CoVaccine HT™ adjuvant, showed durable immunogenicity and ambient-temperature stability in rodent models, followed by non-human primate studies achieving 100% protection. The single-vial design allows shipping at room temperature and reconstitution with sterile water, simplifying field deployment.
3. Strategic and Valuation Implications
Advancing a thermostable Bundibugyo vaccine under CEPI funding could strengthen Soligenix’s position in epidemic preparedness and attract additional partnerships. Successful development may boost the company’s valuation by addressing logistical challenges in endemic regions and expanding its biodefense portfolio.
